Skip to content
value.today

CytRx Corporation

CYTR
$26 Mlast known market cap, Jan 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2024
Net income
$-2 M
SEC filing
Employees
—

CytRx Corporation in brief

CytRx Corporation is a listed company in the Biotechnology industry, based in Los Angeles, USA. Its last known market value was $26 M (January 2022); there is no current figure. Its shares trade under the symbol CYTR (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About CytRx Corporation

CytRx Corp. is a biopharmaceutical research and development oncology company based in Los Angeles, California.

The CytRx oncology pipeline includes clinical trials involving their lead drug aldoxorubicin. Aldoxorubicin (formerly INNO-206) is a modified form of doxorubicin, the popular anthracycline chemotherapeutic agent known as "red death".

Anthracyclines are a class of drugs that are among the most commonly used agents in the treatment of cancer. Doxorubicin, the first anthracycline to gain approval, has demonstrated efficacy in a wide variety of cancers including breast cancer, lung cancer, sarcomas, and lymphomas. However, doxorubicin is associated with side effects such as myelosuppression, gastrointestinal disorders, mucositis, stomatitis, cumulative cardiotoxicity and extravasation.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

CytRx Corporation timeline

3 events, 1990–2022
  1. 1990
  2. 🔔
    · approximate
    Initial public offering on Nasdaq as CYTR
  3. 1995
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2022
  6. ✎
    Renamed LadRx Corp
    Formerly Cytrx Corp.

Events of CytRx Corporation from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
—
Liabilities / assets
269.0%
Net debt
$-38M
Revenue growth
+150.0%
R&D / revenue
156.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue $0M, net income $-35M$0MFY17Fiscal year ending Dec 2018: revenue $0M, net income $-13M$0MFY18Fiscal year ending Dec 2019: revenue —, net income $-7M—FY19Fiscal year ending Dec 2020: revenue —, net income $-7M—FY20Fiscal year ending Dec 2021: revenue —, net income $-13M—FY21Fiscal year ending Dec 2022: revenue —, net income $-4M—FY22Fiscal year ending Dec 2023: revenue —, net income $0M—FY23Fiscal year ending Dec 2024: revenue —, net income $-2M—FY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024——$-4M$-2M—
Dec 2023——$-4M$0M—
Dec 2022——$-5M$-4M—
Dec 2021——$-12M$-13M—
Dec 2020——$-7M$-7M—
Dec 2019——$-8M$-7M—
Dec 2018$0M+150.0%$-8M$-13M-5084.0%
Dec 2017$0M—$-28M$-35M-34990.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$-1M——$-3.21—
Dec 2023$1M——$0.68—
Dec 2022$-5M$0M$-5M$-0.11—
Dec 2021$-12M$0M$-12M$-0.35—
Dec 2020$-6M$0M$-6M$-0.19—
Dec 2019$-6M$0M$-6M$-0.22—
Dec 2018$-11M$0M$-11M$-0.41—
Dec 2017$-27M$0M$-27M$-1.46—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Jun 2023: revenue —, net income $3M—Jun ’23Three months to Sep 2023: revenue —, net income $-1M—Sep ’23Three months to Dec 2023 (from the annual report): revenue —, net income $-1M—Dec ’23Three months to Mar 2024: revenue —, net income $0M—Mar ’24Three months to Jun 2024: revenue —, net income $-1M—Jun ’24Three months to Sep 2024: revenue —, net income $-1M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $0M—Dec ’24Three months to Mar 2025: revenue —, net income $-1M—Mar ’25

Latest quarter to Mar 2025: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Mar 2025.

SEC filings

Official filings of CytRx Corporation with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-4 M
Net income
$-2 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$1 M
Total liabilities
$2 M
Total equity
$-1 M

As of December-2024

Insider trading at CytRx Corporation#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
12
since
CytRx Corporation: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jennifer K. SimpsonDirectorGrant or award+25,000——25,000Form 4
filed Earl W. BrienDirectorOption exercise+150,000$0.260$39 K590,247Form 4
filed Joel K. CaldwellDirectorOption exercise+450,000$0.260$117 K510,000Form 4
filed Steven A. KriegsmanChief Executive Officer, DirectorOption exercise+3.00 M$0.260$780 K4.83 MForm 4
filed Louis IgnarroDirectorOption exercise+700,000$0.260$182 K872,427Form 4
filed Joel K. CaldwellDirectorShares withheld for tax-174,627$0.670$117 K335,373Form 4
filed Louis IgnarroDirectorShares withheld for tax-271,642$0.670$182 K600,785Form 4
filed Steven A. KriegsmanChief Executive Officer, DirectorShares withheld for tax-1.16 M$0.670$780 K3.67 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: CytRx Corporation#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Buybacks, Q4 2015
$0M
Q4 2015

Stock splits: 6-for-1 split in the period to

Bankruptcy filing: (8-K)

CytRx Corporation share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2015Q4 2015$0M
Q4 2014Q4 2014$0M
Q4 2013Q4 2013$0M
Q3 2013Q3 2013$0M
Q4 2012Q4 2013$0M
Q3 2012Q3 2013$0M

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

CytRx Corporation scorecard#

Passes 2 of the 7 checks that could be worked out. Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-3.21 vs 0.68Diluted EPS -3.21 in fiscal 2024 against 0.68 the year before (report's currency).
    • ✓Net income higher than five years earlier-$2 M-$2 M in fiscal 2024 against -$7 M in 2019.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2024.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2024.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.37 at the end of fiscal 2024.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.4%Diluted shares up 1.4% in fiscal 2024.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

CytRx Corporation: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

CytRx Corporation: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015
Income statement
Revenue——————0.30.1——
Research and development0.80.3——0.80.40.416r3643
General and administrative2.83.54.56.06.07.48.1131620
Operating expenses3.63.84.6126.87.98.528——
Total costs and expenses———————335263
Operating income−3.6−3.8−4.6−12−6.8−7.9−8.2−28r−52−63
Interest and finance income————0.10.40.40.40.30.2
Interest expense and finance costs——————1.73.82.80
Other non-operating income (expense)—0.0−0.0−0.00.0−0.00.00.0r0.20.0
Income before tax———−13−6.7−7.5−9.1−30r−51−59
Income tax————0.00.0r−0.0r0.00.00.0
Income from continuing operations————−6.7−7.5−9.1−30——
Income from discontinued operations—————0.4−3.6r4.5——
Net income attributable to shareholders−1.60.4−4.2−13−6.7−7.2−13−35−51−59
Earnings per share, basic-3.210.68-0.11-0.35-0.19-0.22-0.41-1.46-3.78r-5.82r
Earnings per share, diluted-3.210.68-0.11-0.35-0.19-0.22-0.41-1.46-3.78r-5.82r
Shares, weighted average (basic)0.50.50.5r38——————
Shares, weighted average (diluted)0.50.50.5383533312414r10r
Balance sheet
Cash and cash equivalents0.82.11.46.810162137r57r22
Receivables—————0.00.17.5r0.24.6r
Other current assets0.10.20.61.31.11.10.91.93.42.4
Current assets0.82.32.08.3111723476164
Property, plant and equipment0.00.00.00.00.00.00.00.1r2.01.5
Right-of-use (leased) assets—0.00.20.40.6—————
Goodwill———————0.20.20.2
Total assets0.82.32.28.7121723486367
Accounts payable1.11.21.01.51.40.91.24.1r6.48.1
Debt due within a year———————115.50
Current liabilities2.32.22.23.72.82.12.6302023
Long-term debt———————0180
Lease liabilities (non-current)——0.00.20.4—————
Total liabilities—2.22.24.03.22.12.6303823
Retained earnings−490−489−489−484−471−464−457−451−416−365
Shareholders' equity−1.40.1−1.30.88.91520182544
Total liabilities and equity0.82.32.28.7121723486367
Shares outstanding0.50.50.5r393634342819r66
Cash-flow statement
Depreciation and amortization0.00.00.00.00.00.00.00.1r0.50.3
Share-based compensation0.1—0.0—0.32.01.63.1r6.77.4
Cash from operating activities−1.31.0−4.8−12−6.1−5.7−11−27r−50−48
Capital expenditure——−0.0−0.0−0.0−0.0−0.0−0.1−1.0−0.3
Cash from investing activities——−0.0−0.0−0.00.5−0.0−0.13410
Debt issued———————0240
Debt repaid——————−10.0−1500
Shares bought back————————00
Cash from financing activities—−0.3−0.69.10.0—−5.28.05127
Change in cash−1.30.7−5.4−3.2−6.1−5.2−16−19r35−10.0
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at CytRx Corporation#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Bankruptcy or receivershipDebt called earlyFiling

Bankruptcy or receivership 1 · Debt called early 1 · Acquisition or sale completed 1 · Directors and officers 8 · Material agreement 2 · Agreement ended 1 · Shareholder rights changed 4 · Bylaws or fiscal year changed 5 · Shareholder vote 4

CytRx Corporation: events reported to the SEC
FiledWhat happenedFiling
Bankruptcy or receivershipDebt called earlyDirectors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Material agreementAgreement ended8-K
Directors and officers8-K/A
Directors and officersShareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Acquisition or sale completedMaterial agreement8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jul 31, 2025

Acquisitions and funding#

Private share sales · funding history

Private share sales of CytRx Corporation
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2021$8 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Feb 2016$1 MPrivate placement after listingUnder $2 million2optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at CytRx Corporation#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2007–2007
Latest
—
2007-05-18
CytRx Corporation: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2007············—
CytRx Corporation: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How CytRx Corporation compares in Biotechnology

  • Revenue growth150.0% · higher than 87% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
CytRx Corporation🇺🇸$26 M——+150.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 7, 2022 (last known)
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, Wikipedia, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at CytRx Corporation? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show CytRx Corporation's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about CytRx Corporation? Suggest a correction